Related Experiment Videos
Fetal intrahepatic cholestasis secondary to BO hemolytic disease
Journal of the National Medical Association
|August 1, 1981
Insights
Severe newborn jaundice due to BO incompatibility can lead to persistent conjugated hyperbilirubinemia. Cholestyramine therapy effectively treated this rare condition in an infant.
Area of Science:
- Neonatal Medicine
- Pediatric Gastroenterology
- Hematology
Background:
- Neonatal hyperbilirubinemia is common, but severe direct hyperbilirubinemia is rare.
- Blood group (BO) incompatibility can cause significant fetal hemolysis and neonatal jaundice.
Observation:
- A neonate presented with severe direct hyperbilirubinemia at four hours of age, linked to BO incompatibility.
- Fetal hemolysis and high indirect bilirubin levels were suspected to induce fetal conjugating enzymes.
- Persistent conjugated hyperbilirubinemia post-birth indicated intrahepatic cholestasis.
Findings:
- The infant experienced severe direct hyperbilirubinemia and intrahepatic cholestasis.
- This condition was successfully treated with cholestyramine therapy.
Implications:
- This case highlights a rare presentation of neonatal jaundice and cholestasis.
- Cholestyramine may be an effective treatment for persistent conjugated hyperbilirubinemia in neonates with BO incompatibility.
- Further research into enzyme induction and cholestasis in hemolytic disease is warranted.
Abstract:
A rare occurrence of severe, direct hyperbilirubinemia in an infant with BO incompatibility was noted at four hours of age. Severe fetal hemolysis and markedly elevated indirect bilirubin levels might have caused induction of conjugating enzymes during fetal life in this case. Intrahepatic cholestasis was responsible for persistent conjugated hyperbilirubinemia after birth. This responded favorably to cholestyramine therapy.